Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
STTK vs COCP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
STTK Captures Overall Composite Edge (51.1 HOLD vs 47.1 HOLD), While COCP Leads 3–2 on Growth & Valuation Pillars
STTK Overall Winner
6-Pillar Tally: STTK 2 – 3 COCP (1 Tie)
Matrix Metrics: STTK 5 – 2 COCP
As of Nov 16, 2026, Shattuck Labs, Inc. (STTK) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (51.1/100 HOLD vs. 47.1/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. STTK trades at $4.56 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.00 (N/M Forward P/E, -3063.6% operating margin).
- Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (51.1/100 HOLD vs. COCP 47.1/100 HOLD) and 1.48β · 78% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.1); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About STTK vs COCP
STTK
Head-to-Head Winner
Shattuck Labs, Inc. Common Stock
$4.56
-1.94% 1D
Market Cap
$474.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.48β · 78% Vol
Unified Composite Score
51.1
HOLD
Tech 48.0
Fund 58.0
Flow 63.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
COCP
Cocrystal Pharma, Inc. Common Stock
$1.00
+1.98% 1D
Market Cap
$19.6M
TTM Revenue
$330,000
Forward P/E
N/M
Beta / 30D Vol
1.04β · 54% Vol
Unified Composite Score
47.1
HOLD
Tech 51.0
Fund 48.0
Flow 50.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (STTK 2 – 3 COCP)
1. Valuation Multiples
COCP
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
49.7x
2. Growth & Scale
COCP
Revenue Growth (YoY)
-66.6%
+26.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$330,000
Market Cap
$474.6M
$19.6M
3. Profitability & Quality
STTK
Gross Margin
N/A
N/A
Operating Margin
0.0%
-3063.6%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-47.2%
-311.7%
4. Balance Sheet & Cash Flow
COCP
Cash Generation (TTM)
-$50M
-$7.6M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$59M Net Cash
$3.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
STTK
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
72.4% (10th %ile)
N/A (N/A)
Put/Call OI Skew
4.54x (Put-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: STTK (5) vs COCP (2)| Institutional Metric | STTK | COCP | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $474.6M | $19.6M | STTK | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -66.6% | +26.9% | COCP | |
| Operating Margin (TTM) | 0.0% | -3063.6% | STTK | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -47.2% | -311.7% | STTK | |
| 52-Week Range Position | 43% ($2–$8) | 19% ($1–$2) | STTK | |
| Beta / 30D Volatility | 1.48β · 78% Vol | 1.04β · 54% Vol | COCP | |
| Unified Institutional Score | 51.1 / 100 (HOLD) | 47.1 / 100 (HOLD) | STTK | |
| Trailing 12M Revenue (USD) | N/A | $330,000 | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 49.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$50M ($59M Net Cash) | -$7.6M ($3.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
COCP +13.86 pp
3M Horizon
COCP +31.34 pp
6M Horizon
COCP +8.32 pp
1Y Horizon
STTK +150.79 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | STTK Revenue | COCP Revenue | STTK Op. Margin | COCP Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2011 | N/A | $10M | N/A | -30.6% | COCP |
| FY2019 | $10M | $10M | -253.5% | -737.4% | STTK |
| FY2020 | $10M | $0M | -371.8% | -476.0% | STTK |
| FY2021 | $30M | N/A | -150.8% | N/A | STTK |
| FY2022 | $0M | N/A | -15848.0% | N/A | STTK |
| FY2023 | $0M | N/A | -5549.6% | N/A | STTK |
| FY2024 | $10M | N/A | -1408.3% | N/A | STTK |
| FY2025 | $0M | N/A | -5150.8% | N/A | STTK |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
STTK
BREAKDOWN
Current IV
72.4%
IV Percentile
10th %ile
Put/Call OI Skew
4.54x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact STTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
COCP
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
STTK Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
COCP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ STTK vs COCP Key Questions & Quantitative Answers
As of Nov 16, 2026, Shattuck Labs, Inc. (STTK) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (51.1/100 HOLD vs. 47.1/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. STTK trades at $4.56 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.00 (N/M Forward P/E, -3063.6% operating margin). Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (51.1/100 HOLD vs. COCP 47.1/100 HOLD) and 1.48β · 78% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.1); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
COCP leads the Growth & Scale pillar: STTK posts -66.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). Across the 8-period historical trajectory (FY2011 to FY2025), STTK cumulative revenue shifted +0.0% while COCP shifted +0.0%. In operating R&D and SG&A reinvestment, STTK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.
COCP screens cheaper on headline valuation multiples. STTK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STTK (-47.2% ROE) versus COCP (-311.7% ROE) capital efficiency.
In options market volatility and institutional positioning, STTK carries 72.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 4.54x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 78% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
COCP vs STTK · Reverse Pair
STTK vs PRLD
· Sector Peer
STTK vs TSHA
· Sector Peer
COCP vs PRPO
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking